[{"orgOrder":0,"company":"Emory University","sponsor":"MAPS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Emory University","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Emory University \/ MAPS","highestDevelopmentStatusID":"12","companyTruncated":"Emory University \/ MAPS"}]

Find Clinical Drug Pipeline Developments & Deals for 3,4-Methylenedioxymethamphetamine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Emory University

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          Emory University

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          Details : The funding will be used for a pilot study examining 3,4-methylenedioxymethamphetamine (MDMA)-assisted massed exposure therapy for post-traumatic stress disorder.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          August 27, 2024

                          Lead Product(s) : 3,4-Methylenedioxymethamphetamine HCl

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : MAPS

                          Deal Size : $0.2 million

                          Deal Type : Funding

                          blank